Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%
M&A / Property Routine +

Gary Payton II Named Chief Athletic Ambassador of Valor

From penny-stock SPAC shell to peptide-play: Vector Science bets on sports-medicine branding and cGMP manufacturing to monetize an $80B market.

By The Northwire Desk — AI Analysis Jun 22, 2026 · 07:40 PAIN · 2.47 Vector Science and Therapeutics Corp.
Executive Summary
  • Vector Science & Therapeutics Corp. (TSXV: PAIN) appointed NBA Champion and Golden State Warriors guard Gary Payton II as Chief Athletic Ambassador for Valor, its newly established sports medicine division.
  • Valor aims to leverage Payton II's professional network and firsthand experience to promote clinically sound, non-addictive injury recovery and pain management solutions tailored to elite athletes.
  • The announcement highlights a documented surge in soft tissue and lower-extremity injuries among NBA players, positioning Valor's biomechanical and transdermal peptide delivery platforms as targeted, precision-focused interventions.
  • Darryl Drake Jr. serves as President of Valor.
Material Impact
  • This is a strategic marketing and brand-building initiative rather than a revenue-generating or clinical milestone.
  • The appointment aligns with the company's stated focus on sports medicine and non-addictive pain management, but it does not alter the fundamental development timeline or financial outlook.
  • The stock has already experienced a parabolic run, rising from $0.37 at listing to $2.47 in roughly six weeks. This announcement is expected and incremental, serving to validate the Valor division's commercial strategy rather than introduce new fundamental value.
  • No immediate impact on cash flow, profitability, or capital requirements is indicated.
PAIN · Price
Company Overview
  • Vector Science & Therapeutics Corp. completed a qualifying transaction (reverse takeover) from OpenSesame Acquisition Corp. on April 24, 2026, listing on the TSXV under ticker PAIN.
  • The company operates in the biotechnology and sports medicine sectors, focusing on biomechanical devices, transdermal peptide delivery, and oncology drug delivery.
  • Core initiatives include the Valor sports medicine division, a partnership with MPP Group LLC for cGMP peptide manufacturing, and a preclinical microneedle catheter platform for intratumoral drug delivery targeting pancreatic cancer.
  • The company targets the $80.8 billion peptide market with 22 novel, shelf-stable formulations.
Read the original news release →

More from Vector Science and Therapeutics Corp.

Jun 30, 2026 · 08:55

Vector Science files provisional patent for magnetic transdermal peptide delivery, targeting De Novo FDA pathway amid rapid pipeline expansion.

M&A / Property Jun 12, 2026 · 07:10

Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform

Management Jun 08, 2026 · 07:50

Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor

Management Jun 02, 2026 · 07:45

Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy

Management May 13, 2026 · 10:48

Vector Science Secures Manufacturing Access Amid Related-Party Scrutiny

Other May 11, 2026 · 08:50

Vector swaps $6M capex for a cGMP key, unlocking shelf-stable peptides and signaling a manufacturing-first game plan.

Other